ASM Microbe 2018: Nosopharm to present new first-in-class clinical candidate to tackle Enterobacter

NOSO-502 is on track to be the first novel antibiotic class for the Enterobacteriaceae infections to be introduced into the clinics for 40 years. First-In-Human (FIH) studies are expected to start in 2020 Lyon, France, June 8, 2018 – Nosopharm, a company dedicated to the research and development of new anti-infective drugs, announces that it has been selected to present its first-in-class clinical candidate, NOSO-502, at today’s New Agents Discovery Summary Session at...

READ MORE...

GamaMabs Pharma to present at 2018 ASCO Annual Meeting results from the First-In-Human clinical stud

Objective responses, good safety and evidence of stimulation of the immune system were observed with GM102 administered as a single agent in the dose-finding escalation part of the study    Paris and Toulouse, France, May 22, 2018 – GamaMabs Pharma, a biotechnology company developing optimized therapeutic antibodies targeting the Anti-Müllerian Hormone Receptor II (AMHRII) for the treatment of cancer, today announces the upcoming presentation of clinical data fro...

READ MORE...

Genoscience Pharma extends its first clinical trial of GN561 in patients with advanced liver cancers

Enrollment is open for patients with intrahepatic cholangiocarcinoma and hepatocarcinoma at Croix-Rousse Hospital in Lyon and at Saint-Joseph Hospital in Paris    Marseille, France, May 22, 2018 — Genoscience Pharma, a clinical-stage biotechnology company dedicated to discovering and developing anticancer drugs, announces today the extension to France of its first-in-human Phase 1b/2a clinical study using the oral small molecule GNS561 in advanced liver cancers (cholangioc...

READ MORE...

Franco-Quebecois Forum for Health Innovation (FFQIS): successful second edition strengthens internat

With a focus on medical imaging, digital health, biomaterials and biomechanics, the event, promoting knowledge sharing and B2B meetings, took place on May 15 and 16 in Paris   Paris and Montreal, May 17, 2018 – Medicen Paris Region, the French Alliance for Life Sciences and Health (Alliance française pour les sciences de la vie et de la santé - Aviesan), MEDTEQ and Polytechnique Montréal and TransMedTech, alongside several French and Quebecois partners...

READ MORE...

Discngine receives €600,000 ($743K) from Bpifrance

Funding will enable company to conduct research program on collaborative large scale three-dimensional data management for biomolecules Paris, France, May 14, 2018 – Discngine, a software company specialized in developing applications for life sciences research, today announces that it has received funding of €600,000 ($743K) from Bpifrance. This figure comprises an interest-free loan of €300,000 and an ‘innovation loan’ of €300,000. The objective is to c...

READ MORE...

Medtech Boston: Bpifrance, French Tech Hub and Medicen Paris Region unveil the eight selected startu

Paris, France, April 16, 2018 – Medtech Boston is a program for medtech and e-health companies (medical devices, connected devices, monitoring or diagnostics products). Created by French Tech Hub, Medicen Paris Region, Bpifrance and Mednest, this program aims to help innovative companies develop their products in the US market. The eight selected companies of this third edition were announced today on the occasion of the preparatory bootcamp. They will attend an intensive week during ...

READ MORE...

The seven French health competitiveness clusters create a network

To increase the visibility of their 1,300 members, including 1,000 SMEs, and promote their economic value, the health clusters will speak with one voice Paris, April 11, 2018 - The seven French health competitiveness clusters - Alsace Biovalley, Atlanpole Biotherapies, Cancer-Bio-Santé, Eurobiomed, Lyonbiopole, Medicen Paris Region and Nutrition-Health-Longevity - announce today that they are stenghtening their collaboration to highlight the results of the activities they have und...

READ MORE...

Paris Region Entreprises, in partnership with GIP Resah and Medicen Paris Region, launches call for

Paris, March 28, 2018 - This call for projects is part of the European project inDemand, which aims to create a new model where institutional health organizations and companies join forces to develop innovative digital solutions with financial support from regional public funds. The aim of the inDemand project is to solve challenges identified by healthcare professionals (doctors, nurses, service managers, etc). Taking these challenges into account then leads to the financing of inn...

READ MORE...

NovAliX enters into cooperation agreement with  Max-Planck spin-off

With exclusive rights to sell purified human 20S proteasome, a promising target for hematological malignancy treatment and cancer drug development, NovAliX will also provide structural biology analysis by X-ray crystallography of the protein complex Illkirch, France, March 26, 2018 – NovAliX, a drug discovery-focused Contract Research Organization (CRO) today announces that it has signed a cooperation agreement with German-based ProteoPlex GmbH, a spin-off company of the Max-Planck...

READ MORE...

Medicen Paris Region and its partners organize second edition of Franco-Québécois Forum for Health

With a focus on medical imaging, digital health, biomaterials and biomechanics, the event will promote collaboration and B2B meetings on May 15 and 16 in Paris   Paris and Montréal, March 21, 2018 – Medicen Paris Region, the leading health competitiveness cluster in Europe, today announces an event organized to strengthen Franco-Quebecois collaborations in the medical technology industry. This second edition of the Franco-Québécois Forum for Health ...

READ MORE...